Back to top
more

AcelRx Pharmaceuticals, Inc. (ACRX)

(Delayed Data from NSDQ)

$3.66 USD

3.66
1,585,684

+0.10 (2.81%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -42.86% and -77.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris (ACRS) Begins Phase II Study on Eczema Candidate

by Zacks Equity Research

Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.

RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation

by Zacks Equity Research

RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AcelRx (ACRX) Looks Good: Stock Adds 5.3% in Session

by Zacks Equity Research

AcelRx (ACRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Is the Options Market Predicting a Spike in AcelRx (ACRX) Stock?

by Zacks Equity Research

Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.

AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Catalyst's (CPRX) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 42.86% and -25.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2020 results.

What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?

by Zacks Equity Research

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

What Awaits Selecta Biosciences (SELB) This Earnings Season?

by Zacks Equity Research

In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.

Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.

Teva (TEVA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

Genmab (GMAB) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Genmab's (GMAB) second-quarter revenues are likely to have been driven by royalties on sales of J&J's Darzalex. Several pipeline candidates are under development.

Sanghamitra Saha headshot

What Bargain Hunting? Tap 5 Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q2 Earnings Expected to Decline

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -33.33% and -85.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About AcelRx Pharmaceuticals (ACRX) Rating Upgrade to Buy

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is a Beat in Store for Sunoco (SUN) This Earnings Season?

by Zacks Equity Research

Stable earnings from expansive fuel distribution assets are likely to have boosted Sunoco's (SUN) Q1 earnings.

AcelRx Pharmaceuticals (ACRX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?

by Zacks Equity Research

During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.

Sanghamitra Saha headshot

Bet on Rising P/E Investing With These Top 5 Stocks

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

AcelRx's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in AcelRx Pharmaceuticals.